Table of Contents
Leukemia Research and Treatment
Volume 2012, Article ID 939021, 11 pages
http://dx.doi.org/10.1155/2012/939021
Review Article

Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia

School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

Received 3 February 2012; Accepted 5 March 2012

Academic Editor: George P. Studzinski

Copyright © 2012 Geoffrey Brown and Philip Hughes. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.statistics.gov.uk/hub/population/aging/older-people.
  2. T. Ogawa, M. Kitagawa, and K. Hirokawa, “Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages,” Mechanisms of Ageing and Development, vol. 117, no. 1-3, pp. 57–68, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Herndler-Brandstetter, B. Weinberger, G. Pfister, D. Weiskopf, and B. Grubeck-Loebenstein, “The aging of the adaptive immune system,” Current Immunology Reviews, vol. 7, no. 1, pp. 94–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. D. L. Schmucker, “Age-related changes in liver structure and function: implications for disease?” Experimental Gerontology, vol. 40, no. 8-9, pp. 650–659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. D. A. Pollyea, H. E. Kohrt, and B. C. Medeiros, “Acute myeloid leukaemia in the elderly: a review,” British Journal of Haematology, vol. 152, no. 5, pp. 524–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. Tallman, D. G. Gilliland, and J. M. Rowe, “Drug therapy for acute myeloid leukemia,” Blood, vol. 106, no. 4, pp. 1154–1163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. H. E. Kohrt and S. E. Coutre, “Optimizing therapy for acute myeloid leukemia,” Journal of the National Comprehensive Cancer Network, vol. 6, no. 10, pp. 1003–1016, 2008. View at Google Scholar · View at Scopus
  8. A. K. Burnett, D. Milligan, A. Goldstone et al., “The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial,” British Journal of Haematology, vol. 145, no. 3, pp. 318–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Estey, “Acute myeloid leukemia and myelodysplastic syndromes in older patients,” Journal of Clinical Oncology, vol. 25, no. 14, pp. 1908–1915, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kuendgen and U. Germing, “Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly,” Cancer Treatment Reviews, vol. 35, no. 2, pp. 97–120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Juliusson, P. Antunovic, A. Derolf et al., “Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry,” Blood, vol. 113, no. 18, pp. 4179–4187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Dombret, E. Raffoux, and C. Gardin, “Acute myeloid leukemia in the elderly,” Seminars in Oncology, vol. 35, no. 4, pp. 430–438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. S. Farag, K. J. Archer, K. Mrózek et al., “Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461,” Blood, vol. 108, no. 1, pp. 63–73, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. H. J. Deeg and B. M. Sandmaier, “Who is fit for allogeneic transplantation?” Blood, vol. 116, no. 23, pp. 4762–4770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Samarut and C. Rochette-Egly, “Nuclear retinoic acid receptors: conductors of the retinoic acid symphony during development,” Molecular and Cellular Endocrinology, vol. 348, no. 2, pp. 348–360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. J. Collins, “Retinoic acid receptors, hematopoiesis and leukemogenesis,” Current Opinion in Hematology, vol. 15, no. 4, pp. 346–351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Bennet, D. Catovsky, M. T. Daniel et al., “Proposals for the classification of acute leukaemias,” British Journal of Haematology, vol. 33, pp. 451–458, 1976. View at Google Scholar
  18. A. Kakizuka, W. H. Miller, K. Umesono et al., “Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML,” Cell, vol. 66, no. 4, pp. 663–674, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Chen, A. Zelent, J. H. Tong et al., “Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia,” Journal of Clinical Investigation, vol. 91, no. 5, pp. 2260–2267, 1993. View at Google Scholar · View at Scopus
  20. F. Grigiani, P. F. Ferrucci, U. Testa et al., “The acute promelocytic leukaemia-specific PML-RARA fusion protein inhibits differentiation and promotes survival of myeloid precursor cells,” Cell, vol. 74, pp. 423–431, 1993. View at Google Scholar
  21. M. A. Sanz, D. Grimwade, M. S. Tallman et al., “Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet,” Blood, vol. 113, no. 9, pp. 1875–1891, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Lengfelder, S. Saussele, A. Weisser, T. Büchner, and R. Hehlmann, “Treatment concepts of acute promyelocytic leukemia,” Critical Reviews in Oncology/Hematology, vol. 56, no. 2, pp. 261–274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Petrie, A. Zelent, and S. Waxman, “Differentiation therapy of acute myeloid leukemia: past, present and future,” Current Opinion in Hematology, vol. 16, no. 2, pp. 84–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Altucci and H. Gronemeyer, “The promise of retinoids to fight against cancer,” Nature Reviews Cancer, vol. 1, no. 3, pp. 181–193, 2001. View at Google Scholar · View at Scopus
  25. D. Grimwade, A. R. Mistry, E. Solomon, and F. Guidez, “Acute promyelocytic leukemia: a paradigm for differentiation therapy,” Cancer Treatment and Research, vol. 145, pp. 219–235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Castagnola, M. Lunghi, A. Corso et al., “Management of acute promyelocytic leukemia relapse in the ATRA era,” Haematologica, vol. 83, no. 8, pp. 714–717, 1998. View at Google Scholar · View at Scopus
  27. X. Thomas, H. Dombret, C. Cordonnier et al., “Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation,” Leukemia, vol. 14, no. 6, pp. 1006–1013, 2000. View at Google Scholar · View at Scopus
  28. M. A. Sanz, M. Labopin, N. C. Gorin et al., “Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation,” Bone Marrow Transplantation, vol. 39, no. 8, pp. 461–469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. W. H. Miller, H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman, “Mechanisms of action of arsenic trioxide,” Cancer Research, vol. 62, no. 14, pp. 3893–3903, 2002. View at Google Scholar · View at Scopus
  30. G. Q. Chen, X. G. Shi, W. Tang et al., “Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells,” Blood, vol. 89, no. 9, pp. 3345–3353, 1997. View at Google Scholar · View at Scopus
  31. J. Ablain and H. De The, “Revisiting the differentiation paradigm in acute promyelocytic leukemia,” Blood, vol. 117, no. 22, pp. 5795–5802, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Ghavamzadeh, K. Alimoghaddam, S. H. Ghaffari et al., “Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy,” Annals of Oncology, vol. 17, no. 1, pp. 131–134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Mathews, B. George, K. M. Lakshmi et al., “Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity,” Blood, vol. 107, no. 7, pp. 2627–2632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Lengfelder, W.-K. Hofmann, and D. Novak., “Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia,” Leukemia, vol. 26, pp. 433–442, 2012. View at Publisher · View at Google Scholar
  35. A. Glasow, N. Prodromou, K. Xu, M. Von Lindern, and A. Zelent, “Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways,” Blood, vol. 105, no. 1, pp. 341–349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Glasow, A. Barrett, K. Petrie et al., “DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia,” Blood, vol. 111, no. 4, pp. 2374–2377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Berglund, E. Björling, P. Oksvold et al., “A genecentric human protein atlas for expression profiles based on antibodies,” Molecular and Cellular Proteomics, vol. 7, no. 10, pp. 2019–2027, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Lim, A. Janzer, A. Becker et al., “Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology,” Carcinogenesis, vol. 31, no. 3, pp. 512–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Hayami, J. D. Kelly, H. S. Cho et al., “Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers,” International Journal of Cancer, vol. 128, no. 3, pp. 574–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Schenk, W. C. Chen, S. Gollner et al., “Inhibition of the LSD1/KDM1 demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia,” Nature Medicine, vol. 18, no. 4, pp. 605–611, 2012. View at Publisher · View at Google Scholar
  41. M. G. Lee, C. Wynder, D. M. Schmidt, D. G. McCafferty, and R. Shiekhattar, “Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications,” Chemistry and Biology, vol. 13, no. 6, pp. 563–567, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Huang, E. Greene, T. M. Stewart et al., “Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 19, pp. 8023–8028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. B. Baylin, “DNA methylation and gene silencing in cancer,” Nature Clinical Practice Oncology, vol. 2, no. 1, pp. S4–S11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. K. L. Rice, I. Hormaeche, and J. D. Licht, “Epigenetic regulation of normal and malignant hematopoiesis,” Oncogene, vol. 26, no. 47, pp. 6697–6714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. P. Issa, “Aging, DNA methylation and cancer,” Critical Reviews in Oncology/Hematology, vol. 32, no. 1, pp. 31–43, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Fenaux, G. J. Mufti, E. Hellstrom-Lindberg et al., “Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study,” The Lancet Oncology, vol. 10, no. 3, pp. 223–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Fenaux, G. J. Mufti, E. Hellstrom-Lindberg, V. Santini, N. Guttermann, and U. Germing, “Azacytidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia,” Journal of Clinical Oncology, vol. 28, pp. 562–569, 2010. View at Google Scholar
  48. N. Sudan, J. M. Rossetti, R. K. Shadduck et al., “Treatment of acute myelogenous leukemia with outpatient azacitidine,” Cancer, vol. 107, no. 8, pp. 1839–1843, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Kotla, S. Goel, S. Nischal et al., “Mechanism of action of lenalidomide in hematological malignancies,” Journal of Hematology and Oncology, vol. 2, article 36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Escoubet-Lozach, I. L. Lin, K. Jensen-Pergakes et al., “Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism,” Cancer Research, vol. 69, no. 18, pp. 7347–7356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Pellagatti, M. Jädersten, A. M. Forsblom et al., “Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 27, pp. 11406–11411, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Sekeres, A. F. List, D. Cuthbertson et al., “Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2253–2258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. D. A. Pollyea, H. E. Kohrt, L. Gallegos, M.E. Figueroa, O. Abdel-Wahab, and S. Bhattacharya, “Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia,” Leukemia. In press. View at Publisher · View at Google Scholar
  54. C. M. Bunce, P. J. French, J. Durham, R. A. Stockley, R. H. Michell, and G. Brown, “Indomethacin potentiates the induction of HL60 differentiation to neutrophils, by retinoic acid and granulocyte colony-stimulating factor, and to monocytes, by vitamin D3,” Leukemia, vol. 8, no. 4, pp. 595–604, 1994. View at Google Scholar · View at Scopus
  55. C. M. Bunce, J. C. Mountford, P. J. French et al., “Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family,” Biochimica et Biophysica Acta, vol. 1311, no. 2, pp. 189–198, 1996. View at Google Scholar · View at Scopus
  56. K. I. Mills, A. F. Gilkes, M. Sweeney et al., “Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells,” FEBS Letters, vol. 440, no. 1-2, pp. 158–162, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. J. C. Desmond, J. C. Mountford, M. T. Drayson et al., “The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs,” Cancer Research, vol. 63, no. 2, pp. 505–512, 2003. View at Google Scholar · View at Scopus
  58. T. M. Penning and M. C. Byrns, “Steroid hormone transforming aldo-keto reductases and cancer,” Annals of the New York Academy of Sciences, vol. 1155, pp. 33–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Y. Liu, Y. H. Hsu, P. C. Pan et al., “Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia,” Carcinogenesis, vol. 29, no. 5, pp. 984–990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Mahadevan, J. DiMento, K. Della Croce et al., “Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia,” American Journal of Hematology, vol. 81, no. 10, pp. 779–786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Björk, B. Johansson, K. Broberg, and M. Albin, “Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study,” Leukemia Research, vol. 33, no. 6, pp. 788–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Birtwistle, R. E. Hayden, F. L. Khanim et al., “The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis,” Mutation Research, vol. 662, no. 1-2, pp. 67–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Asou, W. Verbeek, E. Williamson et al., “Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids.,” International Journal of Oncology, vol. 15, no. 5, pp. 1027–1031, 1999. View at Google Scholar · View at Scopus
  64. S. L. Fenton, M. T. Drayson, M. Hewison, E. Vickers, G. Brown, and C. M. Bunce, “Clofibric acid: a potential therapeutic agent in AML and MDS,” British Journal of Haematology, vol. 105, no. 2, pp. 448–451, 1999. View at Google Scholar · View at Scopus
  65. F. L. Khanim, R. E. Hayden, J. Birtwistle et al., “Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia,” PLoS ONE, vol. 4, no. 12, Article ID e8147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. J. A. Murray, F. L. Khanim, R. E. Hayden et al., “Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML),” British Journal of Haematology, vol. 149, no. 1, pp. 65–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. X. H. Tang and L. J. Gudas, “Retinoids, retinoic acid receptors, and cancer,” Annual Review of Pathology, vol. 6, pp. 345–364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. F. X. Ruiz, S. Porté, O. Gallego et al., “Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily,” Biochemical Journal, vol. 440, pp. 335–344, 2011. View at Google Scholar
  69. E. Soppi, K. H. Robert, and G. Gahrton, “Clonal analysis of the response of HL-60 cells to retinoic acid and vitamin D in the presence or absence of leukocyte-conditioned medium,” European Journal of Haematology, vol. 41, no. 1, pp. 66–73, 1988. View at Google Scholar · View at Scopus
  70. M. Kizaki, Y. Ikeda, R. Tanosaki et al., “Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-α and retinoid X receptor-α RNA by HL-60 cells,” Blood, vol. 82, no. 12, pp. 3592–3599, 1993. View at Google Scholar · View at Scopus
  71. H. C. Hsu, W. H. Tsai, M. L. Hsu, C. H. Ho, and S. Y. Wang, “Effects of colony-stimulating factors on the all-trans retinoic acid-induced differentiation of acute promyelocytic leukemic cells,” Chinese Medical Journal, vol. 57, no. 2, pp. 93–99, 1996. View at Google Scholar · View at Scopus
  72. L. E. Purton, S. Dworkin, G. H. Olsen et al., “RARγ is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation,” Journal of Experimental Medicine, vol. 203, no. 5, pp. 1283–1293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. R. G. Keedwell, Y. Zhao, L. A. Hammond et al., “An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium,” British Journal of Cancer, vol. 91, no. 3, pp. 580–588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. S. E. Plyte, K. Hughes, E. Nikolakaki, B. J. Pulverer, and J. R. Woodgett, “Glycogen synthase kinase-3: functions in oncogenesis and development,” Biochimica et Biophysica Acta, vol. 1114, no. 2-3, pp. 147–162, 1992. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Huang, Y. Zhang, A. Bersenev et al., “Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice,” Journal of Clinical Investigation, vol. 119, no. 12, pp. 3519–3529, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. S. M. Kornblau, R. Tibes, Y. H. Qiu et al., “Functional proteomic profiling of AML predicts response and survival,” Blood, vol. 113, no. 1, pp. 154–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. Z. Wang, K. S. Smith, M. Murphy, O. Piloto, T. C. P. Somervaille, and M. L. Cleary, “Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy,” Nature, vol. 455, no. 7217, pp. 1205–1209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. Z. Wang, M. Iwasaki, F. Ficara et al., “GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis,” Cancer Cell, vol. 17, no. 6, pp. 597–608, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Holmes, T. A. O'Brien, R. Knight et al., “Glycogen synthase kinase-3β inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth,” Stem Cells, vol. 26, no. 5, pp. 1288–1297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Bertrand, M. Despeaux, S. Joly et al., “Sex differences in the GSK3β-mediated survival of adherent leukemic progenitors,” Oncogene, vol. 31, pp. 694–705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. J. A. Sokoloski, J. Li, A. Nigam, and A. C. Sartorelli, “Induction of the differentiation of HL-60 and WEHI-3B D+ leukemia cells by lithium chloride,” Leukemia Research, vol. 17, no. 5, pp. 403–410, 1993. View at Publisher · View at Google Scholar · View at Scopus
  82. A. M. Rice, J. Li, and A. C. Sartorelli, “Combination of all-trans retinoic acid and lithium chloride surmounts a retinoid differentiation block induced by expression of Scl and Rbtn2 transcription factors in myeloid leukemia cells,” Leukemia Research, vol. 28, no. 4, pp. 399–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. A. M. Rice, K. M. Holtz, J. Karp, S. Rollins, and A. C. Sartorelli, “Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia,” Leukemia Research, vol. 28, no. 11, pp. 1227–1237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Y. Song, P. Palladinetti, G. Klamer et al., “Glycogen synthase kinase-3β inhibitors suppress leukemia cell growth,” Experimental Hematology, vol. 38, no. 10, pp. 908–921, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. M. R. Mirlashari, I. Randen, and J. Kjeldsen-Kragh, “Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway,” Leukemia Research, vol. 36, no. 4, pp. 499–508, 2011. View at Google Scholar
  86. J. Si, L. Mueller, and S. J. Collins, “GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells,” Leukemia, vol. 25, pp. 1914–1918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Gupta, F. Gulen, L. Sun et al., “GSK3 is a regulator of RAR-mediated differentiation,” Leukemia. In press. View at Publisher · View at Google Scholar
  88. R. A. Finch, J. Li, T. C. Chou, and A. C. Sartorelli, “Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid-treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation,” Blood, vol. 96, no. 6, pp. 2262–2268, 2000. View at Google Scholar · View at Scopus
  89. A. M. Rice and A. C. Sartorelli, “Inhibition of 20 S and 26 S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by all-trans-retinoic acid,” Journal of Biological Chemistry, vol. 276, no. 46, pp. 42722–42727, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. N. Ahmed and M. J. Weidemann, “Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells,” Leukemia Research, vol. 19, no. 4, pp. 263–273, 1995. View at Publisher · View at Google Scholar · View at Scopus
  91. R. D. Knight, J. Mangum, and D. L. Lucas, “Inosine monophosphate dehydrogenase and myeloid cell maturation,” Blood, vol. 69, no. 2, pp. 634–639, 1987. View at Google Scholar · View at Scopus
  92. B. M. Goldstein, J. F. Leary, B. A. Farley, V. E. Marquez, P. C. Levy, and P. T. Rowley, “Induction of HL60 cell differentiation by tiazofurin and its analogues: characterization and efficacy,” Blood, vol. 78, no. 3, pp. 593–598, 1991. View at Google Scholar · View at Scopus
  93. K. W. Pankiewicz, K. B. Lesiak-Watanabe, K. A. Watanabe et al., “Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia,” Journal of Medicinal Chemistry, vol. 45, no. 3, pp. 703–712, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. R. Yazdanparast, M. A. Moosavi, M. Mahdavi, and M. H. Sanati, “3-Hydrogenkwadaphnin from Dendrostellera lessertii induces differentiation and apoptosis in HL-60 cells,” Planta Medica, vol. 71, no. 12, pp. 1112–1117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. M. A. Moosavi, R. Yazdanparast, and A. Lotfi, “3-Hydrogenkwadaphnin induces monocytic differentiation and enhances retinoic acid-mediated granulocytic differentiation in NB4 cell line,” Journal of Biochemistry and Molecular Biology, vol. 39, no. 6, pp. 722–729, 2006. View at Google Scholar · View at Scopus
  96. M. Meli, M. Tolomeo, M. Grifantini et al., “The synergistic apoptotic effects of thiophenfurin, an inosine monophosphate dehydrogenase inhibitor, in combination with retinoids in HL60 cells.,” Oncology Reports, vol. 17, no. 1, pp. 185–192, 2007. View at Google Scholar · View at Scopus
  97. S. H. Ghaffari, N. Shayan-Asl, A. H. Jamialahmadi, K. Alimoghaddam, and A. Ghavamzadeh, “Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival,” Annals of Oncology, vol. 19, no. 11, pp. 1927–1934, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. L. Liu, J. B. Berletch, J. G. Green, M. S. Pate, L. G. Andrews, and T. O. Tollefsbol, “Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation,” Molecular Cancer Therapeutics, vol. 3, no. 8, pp. 1003–1009, 2004. View at Google Scholar · View at Scopus
  99. E. Savoysky, K. Yoshida, T. Ohtomo et al., “Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells,” Biochemical and Biophysical Research Communications, vol. 226, no. 2, pp. 329–334, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. T. W. Reichman, J. Albanell, X. Wang, M. A. Moore, and G. P. Studzinski, “Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein,” Journal of Cellular Biochemistry, vol. 67, pp. 13–23, 1997. View at Google Scholar
  101. W. K. Love, J. B. Berletch, L. G. Andrews, and T. O. Tollefsbol, “Epigenetic regulation of telomerase in retinoid-induced differentiation of human leukemia cells,” International Journal of Oncology, vol. 32, no. 3, pp. 625–631, 2008. View at Google Scholar · View at Scopus
  102. O. Yamada, K. Ozaki, M. Nakatake, M. Akiyama, K. Kawauchi, and R. Matsuoka, “Multistep regulation of telomerase during differentiation of HL60 cells,” Journal of Leukocyte Biology, vol. 83, no. 5, pp. 1240–1248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. F. Pendino, C. Dudognon, F. Delhommeau et al., “Retinoic acid receptor α and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death,” Oncogene, vol. 22, no. 57, pp. 9142–9150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. F. Pendino, J. Hillion, C. Dudognon et al., “Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL,” Leukemia, vol. 20, no. 4, pp. 599–603, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. S. R. Frankel, A. Earley, G. Lauwers et al., “The “retinoic acid syndrome” in acute promyelocytic leukemia,” Annals of Internal Medicine, vol. 117, no. 4, pp. 292–296, 1992. View at Google Scholar
  106. Y. C. Su, P. Dunn, L. Y. Shih et al., “Retinoic acid syndrome in patients following the treatment of acute promyelocytic leukemia with all-trans retinoic acid,” Chang Gung Medical Journal, vol. 32, no. 5, pp. 535–542, 2009. View at Google Scholar · View at Scopus
  107. P. Kastner, H. J. Lawrence, C. Waltzinger, N. B. Ghyselinck, P. Chambon, and S. Chan, “Positive and negative regulation of granulopoiesis by endogenous RARα,” Blood, vol. 97, no. 5, pp. 1314–1320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  108. P. J. Hughes, Y. Zhao, R. A. Chandraratna, and G. Brown, “Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARα and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways,” Journal of Cellular Biochemistry, vol. 97, no. 2, pp. 327–350, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. C. Robert, L. Delva, N. Balitrand et al., “Apoptosis induction by retinoids in eosinophilic leukemia cells: implication of retinoic acid receptor-α signaling in all-trans-retinoic acid hypersensitivity,” Cancer Research, vol. 66, no. 12, pp. 6336–6344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. L. A. Hammond, C. H. V. Krinks, J. Durham et al., “Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells,” British Journal of Cancer, vol. 85, no. 3, pp. 453–462, 2001. View at Publisher · View at Google Scholar · View at Scopus
  111. L. A. Hammond, G. Brown, R. G. Keedwell, J. Durham, and R. A. S. Chandraratna, “The prospects of retinoids in the treatment of prostate cancer,” Anti-Cancer Drugs, vol. 13, no. 8, pp. 781–790, 2002. View at Publisher · View at Google Scholar · View at Scopus